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Abstract 
The use of specific terms under different meanings and varying definitions 
has always been a source of confusion in science. When we point our efforts 
towards an evidence based medicine for inflammatory bowel diseases (IBD) 
the same is true: Terms such as “mucosal healing” or “deep remission” as 
endpoints in clinical trials or treatment goals in daily patient care may 
contribute to misconceptions if meanings change over time or definitions are 
altered.  
It appears to be useful to first have a look at the development of terms and 
their definitions, to assess their intrinsic and context-independent problems 
and then to analyze the different relevance in present-day clinical studies 
and trials. The purpose of such an attempt would be to gain clearer insights 
into the true impact of the clinical findings behind the terms. It may also 
lead to a better defined use of those terms for future studies.  
The terms „mucosal healing“ and „deep remission” have been introduced in 
recent years as new therapeutic targets in the treatment of IBD patients. 
Several clinical trials, cohort studies or inception cohorts provided data that 
the long term disease course is better, when mucosal healing is achieved. 
However, it is still unclear whether continued or increased therapeutic 
measures will aid or improve mucosal healing for patients in clinical 
remission. Clinical trials are under way to answer this question. Attention 
should be paid to clearly address what levels of IBD activity are looked at. In 
the present review article authors aim to summarize the current evidence 
available on mucosal healing and deep remission and try to highlight their 
value and position in the everyday decision making for gastroenterologists. 
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Core tip: 
 
 “Mucosal healing” and “deep remission” have been discussed heavily as 
“new” treatment goals in IBD patients in recent years. This was based on 
evidence that the long term disease behaviour appears to be better, when 
mucosal healing is achieved. Unfortunately, a definite proof that therapy 
escalation for patients in clinical remission not achieving mucosal healing 
will be beneficial is still lacking. Clinical trials are under way to answer this 
question. At the moment it appears to be helpful to summarize the current 
evidence available on mucosal healing and deep remission to support the 
everyday decision making for gastroenterologists. 
 
98 words 
 
 
Introduction 
Assessing the activity of inflammatory bowel disease (IBD) is important for 
our daily practice treating patients with these chronic inflammatory 
diseases. The assessment of disease activity will guide our therapeutic 
decision and our choice of medication. Furthermore it is most important for 
clinical investigations of new treatment options and new drugs. The 
reduction of disease activity remains the most important endpoint in clinical 
trials. 
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However, the discussion on which parameters are most useful for this 
purpose is still ongoing and unresolved.  
Assessment of activity of inflammatory bowel disease (IBD) can be performed 
on different levels such as clinical activity, biochemical activity (eg. by 
measuring CRP or fecal calprotectin), endoscopy, and histology. Clinical 
remission in a given IBD patient does not necessarily imply biochemical, 
endoscopic, or histologic remission. To evaluate biochemical, endoscopic, 
and histologic activity, an increasing degree of invasive measures (blood 
sample, endoscopy, biopsies) is required. Assessing activity in IBD has 
thereby analogies to the iceberg phenomenon where the clinical assessment 
on the surface may show clinical remission, but inflammatory activity may 
still be present on biochemical, endoscopic, and histologic level (Figure 1).  
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Histological remission as initial definition of mucosal healing 
One of the first scientists and clinicians that used the term “healing” or 
“mucosal healing” within the field of IBD was Burton I. Korelitz, past chief of 
the Division of Gastroenterology at Lenox Hill Hospital in New York [1]. 
However, he used this term exclusively with respect to histological changes 
of the mucosa [1]. So when the term “mucosal healing” was introduced into 
IBD clinic it meant the absence of histological alterations of the mucosa. 
Korelitz was well aware that healing of IBD is not regarded to be possible as 
both Crohn’s disease (CD) and ulcerative colitis (UC) are regarded to be 
chronic diseases without spontaneous healing [2]. There may be an absence 
of symptoms and flares over years but mucosal inflammation may re-occur 
after remission for years or even decades (Figure 1). 
Histological healing is difficult to determine especially in Crohn’s disease as 
the inflammation may be patchy and a biopsy could miss an inflammatory 
infiltrate only a few millimeters away [3]. Similarly, in UC the histological 
evaluation of a biopsy may be misleading [4]. Histological alterations may be 
absent from the rectum and sigmoid due to effective topical therapy despite 
the presence of inflammation further proximal in the colon that may not be 
obvious to the endoscopist [4, 5]. Histological healing would mean that we 
have to be sure that there had been an inflammatory infiltrate at a specific 
localization that completely disappeared upon therapy (or spontaneously). As 
is obvious this is hard or even impossible to prove as this would require 
frequent endoscopies with many biopsy samples and a labeling of former 
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biopsy locations. Due to the impracticability of this approach the overall 
acceptance of the concept of “histological healing” was very limited. [5].  Of 
note, newer techniques such as endomicroscopy suffer from the same 
shortcomings.  
 
Endoscopic remission as a new concept for mucosal healing. 
In contrast to the initial concept of “mucosal healing” as a “disappearance of 
inflammatory infiltrate” [2] recent original manuscripts and reviews on the 
topic have used the term under different meanings. The “newer” meanings of 
“mucosal healing” have been summarized again by Korelitz in a critical 
review [2]. One of the “newer meanings” of mucosal healing would be the 
absence of inflammation (“healed mucosa”) to the eye of the endoscopist, a 
definition that now has been applied in many clinical trials [6-16].  
There is an obvious problem with this definition. One must assume the 
location of endoscopically normal mucosa has previously been inflamed[2]. 
Certainly this is easier to assess with endoscopy rather than histology as the 
area of evaluation is larger and small local differences and a patchy pattern 
would play a less important role. Nevertheless it requires that two 
endoscopical examinations are compared.  
The definition also ignores that in endoscopically normal appearing mucosa 
there still may be histological inflammation. Another problem of this 
definition of course is that the inter-observer reproducibility of endoscopical 
IBD scores usually is very poor [17] and depends on the experience of the 
endoscopist [18] regardless of the technique used [19, 20] (it may be discussed 
whether a kappa between 0.7 and 0.8 is satisfying). Usually endoscopic 
Rogler et al. Mucosal healing and deep remission 9 
   
findings are assessed on fixed point scales or described by dichotomous 
variables (present/absent) [18, 21]. However, as outlined by de Lange and 
colleagues “endoscopic features of mucosal inflammation are continuous 
variables” for which dichotomous decisions are artificial and always require 
individual decisions [18]. The question arises how to interpret endoscopical 
findings indicating a clearly improved appearance of the mucosa in 
endoscopy with some or few remaining scattered erosions. A further 
important question arises with respect to endoscopical findings that cannot 
be interpreted as present inflammation but as residuals of former 
inflammation and a lack of complete normalization of the mucosa. Such 
findings would be pseudopolyps in an otherwise normal-appearing colon. 
 
Biochemical (fecal markers) remission as mucosal healing 
 
Fecal markers such as calprotectin or lactoferrin correlate very well with the 
degree and extent of infiltration of the mucosa by leukocytes. A good 
correlation between fecal calprotectin and the Crohn’s Disease Endoscopic 
Index of Severity (CDEIS) was reported in several studies [22, 23]. There is also 
a good correlation of fecal calprotectin with the Simple Endoscopic Score for 
Crohn’s disease (SES-CD) which itself has a strong correlation with the 
CDEIS (correlation coefficient r = 0.920) and an excellent inter-observer 
reliability (κ coefficients 0.791 – 1.000) [24]. 
In ulcerative colitis calprotectin correlates well with disease activity as 
determined by histology and endoscopy [25, 26]. 
It is a familiar experience to endoscopists that the mucosa may appear 
completely normal (healed) in patients that still have a markedly elevated 
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fecal calprotectin. This would be an endoscopic remission but not 
biochemical remission, most likely reflecting a lack of histological remission 
with neutrophils still being present in the mucosal wall. It has been well 
established that calprotectin better correlates with histological findings (at 
least in UC) as compared to serum parameters or endoscopy [27-29] .   
 
Mucosal healing and deep remission: The confused clinician 
Surprisingly, some recent trials have reported a higher relative amount of 
patients with mucosal healing compared to the percentage of patients with 
clinical remission, especially in UC [30]. In those trials usually the 
endoscopist defined whether mucosal healing was present. How can this be 
explained? One reason could be that those patients had concomitant 
irritable bowel syndrome that was responsible for their complaints but no 
relevant remaining inflammation (“IBS superimposed on IBD”). The 
argument is straight forward and logical but it probably does not explain all 
cases. Firstly, little or no information is available on the histological 
remission in those patients. Histological remission – if evaluated by biopsies 
– again may be patchy and the evaluated biopsies may not be representative. 
Damage to deeper layers of the mucosa may have occurred that are not 
visible to the endoscopist’s eye. Therefore is has to be challenged whether 
healed mucosa to the eye of the endoscopist is indeed the “most satisfying 
objective confirmation to support the clinical response” as outlined by 
Korelitz [2]. As he states the endoscopic healing “might be satisfactory for 
comparison in time for response to therapy in an individual case, but not for 
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mucosal healing as an entity and certainly not to be used as an index of 
response to therapy in trials.” [2] 
To minimize the subjective component many clinical trials now apply the 
principle of a “central reader”. Not only does this make trials more 
complicated, more expensive and more time consuming. It substitutes the 
problem of a bias introduced by many subjective evaluations of the mucosal 
response to a bias introduced by one subjective interpretation of findings. 
The intra-observer agreement for many endoscopic scores is not satisfactory. 
It may well be argued that the subjective criteria used by a central reader 
may not be accepted by others and that there could be a reduction of bias by 
a “multi-subjective” view (as we assume is the case for multicenter trials as 
compared to monocentric studies). Of note, in a recent randomized-
controlled trial in patients with UC the conclusion was significantly changed 
after blinded central review of endoscopic images, suggesting that central 
reading of endoscopy may be necessary for regulatory purposes [31]. However, 
the question about the best method of objective endoscopic assessment is far 
from being answered. 
Korelitz suggested that histological healing should be the “minimal criterion 
for mucosal healing and preferably this information should be derived from 
multiple biopsy sites of previous inflammation” [2]. However, this would 
implicate that the evaluation of inflammation by a pathologist is objective. 
There have been studies on the inter-observer and intra-observer agreement 
of pathology findings [32]. Those results are not very encouraging. When a 
number of established criteria were used (excess of histiocytes in 
combination with a villous or irregular aspect of the mucosal surface and 
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granulomas) experienced pathologists could correctly classify 70% of CD 
patients and 75% of UC patients [32]. Especially in mild disease, there is still 
dispute as to whether the presence of a „physiological (minor) inflammation“ 
should be regarded as manifestation of IBD or not. Clinically unaffected 
siblings of IBD patients may show mild histological inflammation and 
increased cellular activation markers [33]. Cell counting will not solve the 
problem. The request for a “central pathology reader” also is not helpful as 
the same dilemma as for the central endoscopy reader will occur. Moreover, 
different pathologists have suggested different criteria to evaluate the 
presence or absence of “un-normal” inflammation (for an overview see [3, 34-
37]. There is no agreement on that. Geboes for example suggested that the 
presence of neutrophils in the intestinal epithelium is an important 
discriminator for the presence or absence of inflammation. He therefore 
suggested that a combination of endoscopy and histology should be used to 
evaluate the presence of inflammation in IBD patients to finally judge 
whether mucosal healing has been achieved (see above). 
 
 
Mucosal healing and deep remission: The confused scientist 
CD and UC are regarded to be chronic diseases that never disappear. The 
concept of a healing of a part of the body affected by such a disease 
subsequently is surprising for scientists working on the elucidation of the 
pathophysiology of IBD. 
However, there is another aspect that is disturbing. There have been reports 
that even in macroscopically and microscopically normal appearing mucosa 
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specific changes can be found that are characteristic for inflammation or at 
least changes that could be associated with the pathophysiology [38-45].  
Changes of the microbiota in the lumen of the gut have been described in 
IBD patients despite the absence of detectable inflammation [46-51]. Could a 
“complete deep remission” be possible without normalization of the intestinal 
microbiome? The mucus layer of the mucosa may be changed also in normal 
appearing mucosa in endoscopy [52-56]. The normal fixation procedure of 
biopsies and the subsequent H&E staining does not allow evaluation of the 
mucus layer as it is destroyed during this procedure. A reduced thickness of 
the mucus layer in UC in remission has been described [54, 56, 57] as well as a 
reduced secretion of mucin [52, 53, 58-60] or defensins [61-64]. The question arises 
whether the mucosa can be termed as “normal” or “healed” if those changes 
are still present. 
Epithelial cells may have an impaired barrier function despite a lack of 
inflammatory signs. Cytokine expression and cytokine secretion by immune 
cells may still be significantly increased despite a normal appearing 
histology. A normalization of those changes has been termed biochemical 
healing [65-68]. There are no data available with respect to the predictive value 
of “biochemical healing” and whether this would correlate to a more 
favorable disease outcome. 
The confused scientist, however, is able to imagine a further level of 
“healing”. In macroscopically normal appearing mucosa with microscopically 
normal appearing cells that display normal cytokine expression and 
secretion levels, epigenetic changes may still be present that may trigger 
pathological responses upon minor stimuli [69-76]. Can a persistence of 
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epigenetic changes in otherwise normal mucosa be termed “mucosal 
healing”? Or do we have to achieve “epigenetic healing” to finally achieve the 
best outcome possible for our patients? These questions will have to be 
answered in the future. Currently we are just at the start of investigations 
into these aspects with the first interesting pieces of the puzzle being put 
together. 
 
 
Mucosal healing and deep remission: The confused “trialist” 
As mentioned above the terms “mucosal healing” and “deep remission” have 
been used in a number of trials with quite different meanings and 
definitions. The key confounder is the lack of unequivocal definition(s). 
Therefore, results and data from those trials with respect to mucosal healing 
cannot easily be compared. Nevertheless, this is done frequently. In most 
cases endoscopical investigation is used for the evaluation of “mucosal 
healing”. One crucial point is whether “mucosal healing” was defined simply 
as the absence of ulcers when ulcers had been seen previously or whether 
the absence of ulcerations and ulcers was investigated exactly at a place 
where those alterations had been found before.  
The above is reflected in the way different trials have been reported. In 
the ACCENT 1 endoscopic sub-study the CDEIS was used for scoring and 
the complete absence of mucosal ulcerations that were observed at baseline 
was evaluated [77]. In the SONIC study in contrast no clearly defined score 
was used. Mucosal healing was defined as “complete absence of mucosal 
ulceration in the colon and terminal ileum” [78]. In the “Top-down versus step 
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up” study by Gert D’Haens and coworkers SES-CD was used for the 
evaluation of mucosal healing which was a secondary endpoint [79, 80]). 
Mucosal healing was defined as “absence of ulcers”. In the MUSIC trials 
again the CDEIS was applied. The definition of mucosal healing was 
“absence of ulcers and endoscopic remission defined as CDEIS < 6”. In the 
EXTEND study applying again SES-CD mucosal healing was seen as 
“absence of mucosal ulceration” [81]. As is obvious from those definitions, the 
question arises whether a few remaining aphthous lesions in a patient with 
severe and deep ulcers at the beginning of therapy also may be termed 
mucosal healing. 
For UC the IOIBD attempted a consensus for mucosal healing in 2007: 
“absence of friability, blood, erosions and ulcers in all visualized segments of 
the gut mucosa”. According to the IOIBD experts the presence of an 
abnormal vascular pattern is still compatible with mucosal healing or 
“normal mucosa”. However, also in UC the definitions applied varied widely: 
In the ACT1 study mucosal healing was a secondary endpoint [82, 83]. The 
Mayo endoscopic subscore was used and mucosal healing was defined as 
“absolute subscore for endoscopy of 0 or 1” [82, 83]. The same definition was 
used for ULTRA 2 [84]. 
In studies on the outcome of therapy with 5-aminosalicylic acid the 
definition of mucosal healing largely defined the number of patients 
achieving this endpoint (Table 1). As an example, Vecchi et al. compared 
mesalazine 4g orally vs. 2+2g orally and enema in 2001 in patients with a 
clinical activity index (CAI) of 4-12 and used an endoscopic Rachmilewitz 
index <4 as definition of mucosal healing leading to 58% vs. 71% of patients 
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achieving this endpoint [85]. In 2002 Malchow compared Mesalazine 4g 
enema vs. 1g foam preparation in patients with a CAI>4 for 4 weeks and 
applied an endoscopic Rachmilewitz index < 2 as definition of mucosal 
healing leading to rates of 38% vs. 37% [86]. As one would expect, the 
different definitions used cause huge variation in defined endoscopic 
mucosal healing rates in patients with UC, which makes the comparison of 
efficacy of different drugs or formulations extremely difficult. 
 
Table 1: 
Association between the definitions of remission and mucosal healing and 
actual healing rates in patients with UC treated with mesalazine (MH). 
Abbreviations: Mc = multicenter, db = double-blind, RCT = randomized 
controlled trial.  
Author Design Study Timing of 
endoscopy 
Endoscopic 
index 
Def. of MH No of pat. 
Achieving 
MH 
Vecchi 
(2001) 
Mc, 
RCT 
Mesalazine 
4g orally vs. 
2+2g orally 
and enema 
6 weeks Rachmilewitz Rachmilewitz 
<4 
58% vs. 
71% 
Malchow 
(2002) 
Mc, 
db, 
RCT 
Mesalazine 
4g enema 
vs. 1g foam 
4 weeks Rachmilewitz Rachmilewitz 
< 2 
38% vs. 
37% 
Mansfield 
(2002) 
Mc, 
db, 
RCT 
Balsalazide 
6.75g vs. 
sulfasal. 3g 
8 weeks 4 point scale Score of 0= 
normal 
mucosa 
27% vs. 
25% 
Hanauer 
(2007) 
Ascend 
Mc, 
db, 
RCT 
Asacol 4.8g 
vs. 2.4g 
6 weeks Descriptive, 
no score 
Normal 
endoscopic 
finding 
25% vs. 
20% 
Kamm 
(2007) 
MMX 
Mc, 
db, 
RCT 
MMX mes. 
4.8g vs. 2.4g 
vs. placebo 
8 weeks Mod. 
Sutherland 
index 
Mod 
Sutherland 
index < 1 
77% vs. 
69% vs. 
46% 
Rogler et al. Mucosal healing and deep remission 17 
   
Kruis 
(2009) 
Mc, 
db, 
RCT 
Mesalazine 
3g vs. 1gx3 
8 weeks Rachmilewitz Rachmilewitz 
<4 
71% VS. 
70% 
 
One of the problems in endoscopic UC scores is the application of varying 
criteria (see table 2) 
 Truelove Baron Powell-T 
(St 
Mark’s) 
Levine Rach-
milewitz 
Modified 
Baron 
Mayo Sutherland 
Erythema      + +  
Edema    +     
Granularity    + + +   
Vascular 
pattern 
 +  + + + +  
Friability  + + + + + + + + 
Erosions    + +  +  
Ulceration    + + + +  
Exudate     +   + 
Remission 0 0-1   0-2 0-1 0-1 0 
 
 
The reasons for such different definitions and endpoints may only be 
speculated.  
Unfortunately we lack an unequivocal definition; all of the scoring systems 
published so far have certain limitations, which have led to the introduction 
of several additional scoring systems. From a patient’s and physician’s 
perspective, however, the use of one single scoring system would be most 
desirable to enable valid comparisons among study outcomes. 
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What is the additive value of deep remission as compared to mucosal 
healing? 
“Deep remission” is another term that has been discussed as a treatment 
target in recent years. The definition, however, is unfortunately not clearer 
than the one of mucosal healing. In the EXTEND study “deep remission” was 
defined as clinical remission (CDAI <150) and complete mucosal healing as 
defined according to CDEIS [13]. It is worthwhile to look a bit closer at this 
definition. If a patient with CD achieves mucosal healing but still has 
increased CDAI (no clinical remission) this may be due to superimposed IBS 
symptoms or the fact that without the presence of inflammation there is 
some bowel damage such as a fibrotic stricture or an internal fistula which 
might contribute to increased bowel frequency. Subsequently the lack of 
clinical remission is important for the patient and his/her clinical 
management (e.g. surgery of the stricture) but not for the medical (anti-
inflammatory) management of the disease. Thus, the term “deep remission” 
in the definition outlined above is not useful and does not provide more 
information than mucosal healing. In fact – it contributes to confusion of 
scientists, clinicians and “trialists”. 
 
How can we improve?  
There should be standards on the definition of mucosal healing for clinical 
studies. It needs to be discussed – and finally decided – whether endoscopic 
mucosal healing, histologic mucosal healing or a combination of both can be 
standardized. Once agreement on definitions has been achieved, a given 
patient could be assessed by a –hopefully- simple binary coded tool that is 
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oriented according to the TNM classification of oncology. A proposal for such 
a tool is illustrated in Table 3. The number “1” stands for “active”, “0” for 
“remission” and “x” for “not assessed”. Of note CD activity assessment would 
require, in contrast to UC, not only measuring clinical activity, biochemical, 
endoscopic and histologic activity, but also imaging modalities (presence of 
fistulas, strictures). This simple approach has the potential to reduce the 
amount of potentially confusing new definitions to describe different 
combinations of activities in IBD.  
Other definitions of mucosal healing (such as “biological mucosal healing”, 
“epigenetic mucosal healing”, “mucus layer healing” or “microbiota mucosal 
healing”) require further studies and prospective trials. At this point they are 
purely investigational and should not be used in clinical trials. 
What would happen if such an agreement cannot be achieved? Then it would 
not make sense to discuss mucosal healing as a treatment target for IBD any 
further as this would be a treatment target that lacks a definition and 
subsequently is blurry, vague and indistinct.  
 
Table 3: proposal of the CBEHI classification to assess CD activity. Example: 
a CD patient with C0B0(CRP)E1H1I0 would have clinical and biochemical 
remission, but endoscopic and histologic activity.  
Activtiy level Definition  Code 
Clinical activity Remission: CDAI <150 
Active: CDAI ≥150 
C0 
C1 
Biochemical activity CRP normal 
Elevated CRP 
B0(CRP) 
B1(CRP) 
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Calprotectin <200µg/g 
Calprotectin ≥200µg/g 
B0(Calpro) 
B1(Calpro) 
Endoscopic activity Remission: SES-CD <4 
Active: SES-CD ≥4 
E0 
E1 
Histologic activity  Inactive 
Active  
H0 
H1 
Imaging  Inactive: no fistulas, no 
stenoses 
Active: presence of either 
fistula and/or stenosis  
I0 
 
I1 
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